Skip to content
Peptilyze
CompoundsShopsCompareMarketLab testsGuidesMethod

Peptides · Reference article

Pinealon and the Huberman Sleep Claim: What the Evidence Shows

A viral post says Huberman called pinealon a six-hour-sleep fix. We traced the post, the pinealon studies, tesamorelin's label and each claim made.

Published · Updated · Rests on: 5 small Russian human reports, cell and rat papers, no registered pinealon trials, FDA tesamorelin label, 2 FDA compounding pages, 4 Huberman and @limitlesstack posts

This is a reference article, not a price comparison. Peptilyze compares prices of research peptides; it sells nothing and gives no medical advice. Every claim is numbered and listed under Sources.

On 2026-10-27 the account @limitlesstack wrote that “according to huberman, pinealon before bed + 6h sleep = waking up like a kid on christmas morning, every time.” The post drew about 1.3 million views [17]. A real Huberman reply exists, but it says less than the post does, and no study we found tests pinealon for sleep.

Key points

  • Andrew Huberman did write a reply mentioning pinealon and tesamorelin on 2025-04-01. It was conditional (“if you’ve ever taken…”), named two substances, and added a fasting condition. “Every time” is the poster’s wording [13][17].
  • Pinealon is a three-amino-acid peptide (Glu-Asp-Arg). Its research is mostly cell and rat work plus a few small Russian human reports. We found no placebo-controlled sleep study [1][3][8].
  • Tesamorelin is an FDA-approved drug for excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for sleep, and the two sleep-focused tesamorelin trials we found were withdrawn [18][21].
  • None of the @limitlesstack claims is supported in people. Learning and memory effects have some rat support only.
  • Long-term human safety data for pinealon do not exist in what we found.

What pinealon is

Pinealon is a synthetic tripeptide, glutamic acid-aspartic acid-arginine (Glu-Asp-Arg, also written EDR) [1]. A 2020 review by the Khavinson group describes it as isolated from Cortexin, a polypeptide neuroprotective drug [2]. It belongs to the “bioregulator” short peptides studied by the Khavinson group in St. Petersburg; see our Khavinson bioregulator evidence review for the wider family.

What the research shows

A PubMed search for “pinealon” on 2026-11-08 returned 22 records [8]. Some are not pinealon studies (a food-protein paper, a general peptide review). ClinicalTrials.gov returned no registered study for the term [9]. For a fuller summary see our pinealon research overview. In brief:

Cell and animal work. A 2011 paper in Rejuvenation Research, with Khavinson as first author and the St. Petersburg Institute of Bioregulation and Gerontology as affiliation, reported that pinealon reduced reactive oxygen species and necrotic cell death in rat cerebellar cells, neutrophils and PC12 cells [1]. A 2012 rat study, again with Khavinson as an author, reported better spatial learning in offspring of rats given a high-methionine diet in pregnancy when pinealon was given [7]. A 2013 rat paper on peptide geroprotectors and navigation learning is known to us by title only [23]. Eight of the 22 records list Khavinson as an author; the cell and animal work we opened is Russian.

Human reports. We opened five human reports, all in the Russian journal Advances in Gerontology, 2012 to 2016:

Report Who What the abstract says
Meshchaninov et al., 2015 [3] 32 adults aged 41-83 with polymorbidity and organic brain syndrome Pinealon and a second peptide (Vesugen) improved biological-age indicators; the abstract also reports pro-oxidant activity and reduced CD34+ cells. No control group is described.
Bashkireva and Artamonova, 2012 [4] 150 lorry drivers and 150 metal workers Peptides, best in combination, improved psycho-emotional indices; the peptide arm is not clearly separated in the abstract.
Nazimko et al., 2012 [5] Locomotive crew workers A two-week course; reported improved “biological age” indicators. Size not stated in the abstract.
Myakotnykh et al., 2016 [6] 110 people of varying ages Pinealon plus Vesugen compared with baths, oxygen therapy and massage; best effect on biological-age scores for the combination.
Bashkireva and Kachan, 2015 [24] Workers with occupational hazards Work-ability index; no sleep outcome.

The 2020 Khavinson review also mentions a 72-patient study in people with after-effects of brain injury, reporting better memory and fewer headaches [2]. We did not open that original report, so we cannot judge its design.

None of these abstracts reports a sleep outcome. A text search of all 22 PubMed records found no pinealon study measuring sleep or sleep deprivation [8]. The human outcomes are “biological age” scores and questionnaires, which are not standard clinical endpoints, and none is described as placebo-controlled or blinded.

Regulatory status

  • United States. We found no FDA approval for pinealon. The FDA page listing Category 2 compounding substances and withdrawn nominations (current as of 2026-04-22) names several peptides, including epitalon, BPC-157 and kisspeptin-10, but not pinealon [10]. The FDA page on 503A bulk substances does not name it either [11]. We checked only these two pages.
  • European Union and others. We found no EMA authorisation or opinion for pinealon. We could not search every national register, and we could not verify UK or German status.
  • Russia. The RLS drug-information site lists “Пинеалон” as a dietary supplement (БАД) in capsule and tablet forms, described as an additional source of peptides, not as a medicine. The page shows no registration number or manufacturer [12].
  • “Research use only” is how shops label peptides sold outside medicine and food rules. It is not an approval, and it does not mean a regulator has checked purity or safety.

The Huberman statement

The screenshot in the source post matches a real reply. Huberman (@hubermanlab) replied on 2025-04-01 at 00:58 UTC to a post by Tim Urban (@waitbutwhy), posted 28 minutes earlier, asking why he stays up the last two hours of each night [13][14]. The reply reads: “if you’ve ever taken Tesamorelin or Pinealon 30min before sleep without having eaten in the previous 2hrs you’re sleeping 6hrs waking like a kid on Xmas morning. Just saying.” [13]

What we could and could not verify:

  • We read the text through a third-party mirror of X data (fxtwitter), because X itself refused automated access. Timestamps match the ID encoding. We did not see the post on X directly.
  • We found no news report quoting or discussing the reply.
  • The date is April 1 (UTC; the evening of March 31 in US time zones). We cannot tell from the text whether it was a joke.
  • The reply does not say “every time,” does not mention a 6-hour result as a study finding, and requires two conditions.
  • Huberman has posted about pinealon at other times: on 2025-01-19 he listed it among sleep aids “if you’re peptide brave,” noting “wow REM increase” [15]. On 2025-08-08 he wrote that some of these peptides are “FDA approved others animal studies only” [16]. We could not verify his podcast remarks on pinealon from a primary transcript.

A podcaster’s post is not evidence either way. It is one person’s report, with no control, no measurement we can inspect and no peer review.

Tesamorelin

Tesamorelin (brand Egrifta) is a growth hormone-releasing factor analog, first approved in the US in 2010. The March 2025 label for Egrifta WR states it is for “reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” It is not for weight loss, and the label says long-term cardiovascular safety is not established [18]. Contraindications include active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. Warnings cover raised IGF-1, fluid retention, and glucose intolerance or diabetes. The most common reactions are joint pain, injection-site reactions, limb pain, swelling and muscle pain [18]. The label text contains no sleep indication or sleep warning.

On sleep: a search of ClinicalTrials.gov found two sleep-focused tesamorelin studies, one in service members with brain injury and insomnia and one on sleep-disordered breathing in HIV. Both were withdrawn [21]. A separate registered trial of a different GHRH compound for age-related sleep disturbances (NCT00000380) is listed as completed; we did not read its results [25]. A 2006 review noted phase II sleep-disorder trials as “underway”; we found no results [22]. A 2012 randomized placebo-controlled trial (152 adults, 20 weeks) and a 2026 pilot (22 adults, 10 weeks, tesamorelin or placebo) studied cognition. The 2026 pilot compared sleep among many measures and reported no significant changes in the study measures [19][20].

How the @limitlesstack claims hold up

The 2026-09-12 post called pinealon the only pill that “can acutely reverse most of the mental effects of sleep deprivation,” and listed faster learning, stronger memory, and “mimics some cognitive benefits of exercise,” ending “for life” [17].

Claim Verdict Why
Acutely reverses effects of sleep deprivation Not supported No study of pinealon in sleep-deprived people or animals in what we found [8].
Faster learning Not supported in humans Rat studies report learning changes in specific injury or stress models [7][23]. None tests healthy people.
Stronger memory Partly supported (animal; unverified human) Rat findings [7]; a review reports a 72-patient brain-injury study we could not open [2].
Mimics exercise benefits Not supported No study compares pinealon with exercise.
“For life” Not supported The only course length stated in the abstracts we read was two weeks [5]; no long-term safety data.
Waking rested on six hours “every time” (attributed to Huberman) Not supported The reply was conditional and is not a study [13].

Risks and unknowns

The 2016 report says it assessed safety and found the peptides among the safest approaches compared, but the abstracts give no adverse-event counts [6]. The 2015 report recorded pro-oxidant activity and a drop in CD34+ blood cells, which its authors read as significant inhibition of haematopoiesis [3]. Whether that matters clinically is unknown. We found no data on interactions, pregnancy, children, long-term use or effect on sleep architecture. Products sold as research chemicals carry additional uncertainty about identity and purity. Tesamorelin has a documented risk profile in HIV lipodystrophy but unknown effects in healthy sleepers [18].

Frequently asked questions

Did Huberman say pinealon gives a rested morning after six hours? He replied to Tim Urban on 2025-04-01 with a conditional sentence mentioning pinealon and tesamorelin, with the condition of no food in the previous two hours [13]. He did not describe a study. The “every time” in the viral post is not in his reply.

Is there human research on pinealon and sleep? We found none. The human reports we opened measured biological-age scores and questionnaires in small groups and did not report sleep [3][4][5][6].

Is tesamorelin approved for sleep? No. Its FDA-approved use is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy [18].

Is pinealon legal? It is not an approved medicine in the sources we checked. Russia lists it as a dietary supplement [12]. We could not verify its status in the UK or Germany.

Sources

  1. Khavinson V, et al., “Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes,” Rejuvenation Research (2011). https://pubmed.ncbi.nlm.nih.gov/21978084/
  2. Khavinson V, Linkova N, Kozhevnikova E, “EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease,” Molecules (2020-12-31). https://pmc.ncbi.nlm.nih.gov/articles/PMC7795577/
  3. Meshchaninov VN, et al., “Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome in remission,” Advances in Gerontology (2015). https://pubmed.ncbi.nlm.nih.gov/26390612/
  4. Bashkireva AS, Artamonova VG, “The peptide correction of neurotic disorders among professional truck-drivers,” Advances in Gerontology (2012). https://pubmed.ncbi.nlm.nih.gov/23734521/
  5. Nazimko VA, et al., “Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades,” Advances in Gerontology (2012). https://pubmed.ncbi.nlm.nih.gov/22708445/
  6. Myakotnykh VS, et al., “Comparative analysis of different methods of geroprotective,” Advances in Gerontology (2016). https://pubmed.ncbi.nlm.nih.gov/28539017/
  7. Arutjunyan A, et al., “Pinealon protects the rat offspring from prenatal hyperhomocysteinemia,” Int J Clin Exp Med (2012). https://pubmed.ncbi.nlm.nih.gov/22567179/
  8. NCBI PubMed, search “pinealon” (22 records; run 2026-11-08). https://pubmed.ncbi.nlm.nih.gov/?term=pinealon
  9. ClinicalTrials.gov, search “pinealon” (no studies; run 2026-11-08). https://clinicaltrials.gov/search?term=pinealon
  10. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  11. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FDCA” (content current 2026-05-14). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  12. RLS (rlsnet.ru), “Пинеалон” dietary supplement entry (undated). https://www.rlsnet.ru/baa/pinealon-30390
  13. Andrew Huberman (@hubermanlab), reply to @waitbutwhy (2025-04-01), read via fxtwitter mirror. https://x.com/hubermanlab/status/1906873861502857318
  14. Tim Urban (@waitbutwhy), post on sleeping six hours (2025-04-01), read via fxtwitter mirror. https://x.com/waitbutwhy/status/1906866707534147681
  15. Andrew Huberman (@hubermanlab), sleep-aids post (2025-01-19), via fxtwitter mirror. https://x.com/hubermanlab/status/1881066373708960030
  16. Andrew Huberman (@hubermanlab), peptides post (2025-08-08), via fxtwitter mirror. https://x.com/hubermanlab/status/1953836918317223948
  17. @limitlesstack, posts of 2026-10-27 and quoted 2026-09-12 (id 2115145487695364467), via fxtwitter mirror and the Peptilyze source file. https://x.com/limitlesstack/status/2115145487695364467
  18. FDA, EGRIFTA WR (tesamorelin) prescribing information (revised 2025-03). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
  19. “Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial,” Archives of Neurology (2012). https://pubmed.ncbi.nlm.nih.gov/22869065/
  20. “The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment,” eNeurologicalSci (2026). https://pubmed.ncbi.nlm.nih.gov/42382101/
  21. ClinicalTrials.gov, NCT02931474 and NCT01788462 (both withdrawn). https://clinicaltrials.gov/study/NCT02931474 ; https://clinicaltrials.gov/study/NCT01788462
  22. “Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor,” Current Opinion in Investigational Drugs (2006). https://pubmed.ncbi.nlm.nih.gov/17086939/
  23. Mendzheritski AM, et al., “Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age,” Advances in Gerontology (2013), title and record only. https://pubmed.ncbi.nlm.nih.gov/28976148/
  24. Bashkireva AS, Kachan EY, “Assessment of work ability index in evaluation of small peptides geroprotective effect,” Advances in Gerontology (2015). https://pubmed.ncbi.nlm.nih.gov/28509489/
  25. ClinicalTrials.gov, NCT00000380, “GHRH for age-related sleep disturbances” (listed as completed; results not read). https://clinicaltrials.gov/study/NCT00000380

This article is information, not medical advice.

More in Peptides